Business·Industry

Olix Pharmaceuticals, Inc. Expands Collaboration with L'Oréal on New RNAi-Based Beauty Pipeline

Research and Development Expands into Nail Health Following Skin and Hair Joint Discovery of Additional siRNA Candidate Compounds Through New Targets

KIM SAE-MI
2026-06-29 09:31:02
Lee Dong-ki, CEO of Olix Pharmaceuticals, Inc. (Photo courtesy of Olix Pharmaceuticals, Inc.)

[Edaily Reporter KIM SAE-MI ] Olix Pharmaceuticals, Inc.(226950)announced on the 29th that it has signed a Pipeline Collaboration Framework Agreement with global beauty company L’Oréal Group (hereinafter “L’Oréal”).

Under this agreement, the two companies plan to combine Olix Pharmaceuticals, Inc.’s RNAi platform technology with L’Oréal’s expertise in beauty science to jointly identify and develop next-generation solutions. The scope of development includes application products across various beauty sectors, such as cosmetics for hair, nail, and skin health.

Last year, the two companies jointly launched a short interfering RNA (siRNA) research program focused on skin and hair regeneration and aging. This agreement, signed separately from their existing collaboration, is notable for expanding the scope of cooperation to include nail health and promoting the discovery of new target-based candidate compounds.

Under the agreement, L’Oréal will provide strategic and scientific expertise in beauty science and fund research for joint development. Olix Pharmaceuticals, Inc. will lead all aspects of the research, including candidate discovery, research and development (R&D), and program management.

This framework agreement is designed to enable the simultaneous advancement of multiple research programs. An Olix Pharmaceuticals, Inc. representative commented, “This agreement demonstrates the potential and scope of application for our ‘OASIS’ platform across various targets and indications.”

This agreement follows L’Oréal’s recent equity investment in Olix Pharmaceuticals, Inc. through its venture fund, BOLD. Olix Pharmaceuticals, Inc. views the expansion of research collaboration following L’Oréal’s strategic investment as a sign that the partnership between the two companies is strengthening.

Lee Dong-ki, CEO of Olix Pharmaceuticals, Inc., said, “The fact that this collaboration follows L’Oréal’s recent strategic investment once again demonstrates both companies’ firm belief in the potential and long-term value of RNAi technology.”

Economy

Corporation

IT·Science

Economy

[Exclusive] ABLE C&C to Establish European Control Tower in the Netherlands

ABLE C&C(078520)is establishing a subsidiary in the Netherlands to serve as the control tower for its European operations. Following the establishment of its UK subsidiary, the company is setting up a…
2026-08-20 04:25:07

Corporation

"Just Enjoy the Barre Class for Now"... Viewori Targets the Wellness Crowd [Report]

On the afternoon of the 18th, at the Vuori pop-up store in Seongsu-dong, Seongdong-gu, Seoul, a different scene unfolded as I passed through the first and second floors—where clothes were displayed—an…
2026-08-19 15:40:50

IT·Science

Lundbeck Explores Other Indications for 'APB-A1'… "A Negative Sign, Even If Development Isn't Halted"

AprilBio Co.,Ltd.(397030)has decided to explore other indications for “APB-A1” (Lu AG22515), a technology it licensed to Lundbeck, after the compound failed to demonstrate the expected clinical effica…
2026-08-19 20:21:02